ArticleGeneral psychiatry2026
Elevated endogenous glucagon-like peptide-1 as a novel Alzheimer's disease biomarker associated with neuroinflammation and Aβ pathology.
Article in General psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alzheimer's disease (AD), a neurodegenerative disorder, is pathologically defined by the accumulation of amyloid-β (Aβ) plaques, hyperphosphorylated tau tangles and sustained neuroinflammation. Glucagon-like peptide-1 (GLP-1), originally characterised as an incretin hormone, is also expressed endogenously in the brain. Although GLP-1 receptor agonists (GLP-1RAs) have demonstrated compelling neuroprotective effects in preclinical AD models, their efficacy in human clinical trials has, thus far, been inconsistent and limited. Moreover, the physiological role and dynamics of endogenous GLP-1 during AD progression remain poorly understood, with studies reporting conflicting findings across different patient cohorts. Aims: This study aimed to characterise serum GLP-1 levels across the Alzheimer's disease cognitive continuum and to examine their associations with neuroinflammation, Aβ pathology, tau pathology, brain atrophy and cognitive decline. Methods: We analysed two independent cohorts (Renji: Results: GLP-1 levels were significantly elevated in both brain tissue and serum of patients with AD compared to controls, with concentrations increasing progressively from cognitively normal individuals through mild cognitive impairment (MCI) to AD dementia. Serum GLP-1 negatively correlated with Montreal Cognitive Assessment (MoCA) cognitive performance and positively correlated with GFAP, pTau217 and brain amyloid burden. Serial mediation analysis suggested that GLP-1 and GFAP were statistically positioned along the association between amyloid burden and tau pathology. Machine learning models combining GLP-1 with other biomarkers achieved diagnostic performance (area under the curve = 0.896). Conclusions: The elevation of endogenous GLP-1 in Alzheimer's disease likely represents a compensatory yet ultimately insufficient response to the underlying pathology. It functions as a multidimensional biomarker, reflecting the integrated neuroinflammatory burden, amyloid deposition and clinical disease severity, and may have potential utility in diagnostic applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.